Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat. (Q51467053)

5 April 2018

title

Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat. (English)

1 reference

5 April 2018

author name string

Charles W Bolten

1

1 reference

5 April 2018

Maria A Payne

2

1 reference

5 April 2018

William G McDonald

3

1 reference

5 April 2018

Patrick M Blanner

4

1 reference

5 April 2018

Robert C Chott

5

1 reference

5 April 2018

Sarbani Ghosh

6

1 reference

5 April 2018

Graciela B Arhancet

7

1 reference

5 April 2018

Nicholas R Staten

8

1 reference

5 April 2018

Eric A Gulve

9

1 reference

5 April 2018

Patrick M Sullivan

10

1 reference

5 April 2018

Alexander E Hromockyj

11

1 reference

5 April 2018

Jerry R Colca

12

1 reference

5 April 2018

language of work or name

English

0 references

publication date

1 June 2007

1 reference

5 April 2018

Diabetes and Vascular Disease Research

published in

1 reference

5 April 2018

volume

4

1 reference

5 April 2018

issue

2

1 reference

5 April 2018

page(s)

117-123

1 reference

5 April 2018

Thiazolidinediones: a new class of antidiabetic drugs

cites work

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

Insulin resistance and insulin sensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

New oral thiazolidinedione antidiabetic agents act as insulin sensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

PPAR gamma and the treatment of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

PNU-91325 increases fatty acid synthesis from glucose and mitochondrial long chain fatty acid degradation: a comparative tracer-based metabolomics study with rosiglitazone and pioglitazone in HepG2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

The role of the adipocyte hormone adiponectin in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.029

21 January 2018

Identifiers

DOI

10.3132/DVDR.2007.029

1 reference

5 April 2018

1 reference

5 April 2018